Loyal Dog Lifespan Drug: LOY-002 and the FDA Path

LOY-002 is a daily, flavored pill developed by Loyal — the trading name of Cellular Longevity, Inc. — intended to extend healthy lifespan in senior dogs. You cannot buy it, and your veterinarian cannot prescribe it yet. The program is moving through the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) under the conditional approval pathway for new animal drugs, and in early 2025 Loyal announced that the agency had granted LOY-002 a reasonable expectation of effectiveness — the effectiveness milestone that pathway requires. Target-animal safety and manufacturing review are the remaining pieces. As of early 2026, no drug has reached full FDA approval for extending canine lifespan, and regulatory status can change month to month, so check CVM's published materials and Loyal's own announcements rather than planning around a date you read somewhere.

What LOY-002 is and how it is meant to work

Loyal is a clinical-stage veterinary medicine company built around an unusual premise: developing drugs aimed at canine aging itself rather than at a single named disease. That premise is what makes the regulatory story interesting, because the animal drug approval system was designed around conditions — arthritis, heart disease, dermatitis — not around the broad decline owners actually watch happen.

The company has described three programs publicly. LOY-001 and LOY-003 target large and giant breeds, built on the long-standing observation that bigger dogs carry higher levels of insulin-like growth factor 1 (IGF-1) and tend to live shorter lives than small dogs; those molecules are aimed at reducing IGF-1 signaling. LOY-002 is the senior-dog program and the one most owners are searching for. It is an oral daily tablet, and the company has described its focus as age-related metabolic dysfunction, including insulin sensitivity, rather than IGF-1 reduction.

The pivotal work behind it is the STAY study, a large, multi-site, placebo-controlled trial run through participating veterinary clinics. Dogs live at home with their families. Owners give the pill daily, keep records and bring their dog in for scheduled examinations. Enrollment was limited to senior dogs above a minimum age and body-weight threshold set by the study protocol, which is why many owners who applied were told their dog did not qualify. The design is notable for the field: a randomized, blinded, owner-and-veterinarian trial in real companion dogs rather than a laboratory colony.

Where the FDA process stands and what conditional approval actually means

FDA's animal drug review is modular. A sponsor submits technical sections — effectiveness, target animal safety, and chemistry/manufacturing/controls — and the agency reviews and accepts each one in turn. Full approval requires substantial evidence of effectiveness across all of them.

Conditional approval is a different route. Expanded conditional approval was created by Congress through the 2018 animal drug user fee amendments, and it allows a sponsor to market a drug after demonstrating safety and manufacturing quality plus a reasonable expectation of effectiveness, while it continues gathering the substantial evidence that full approval demands. A conditionally approved animal drug must be renewed annually and cannot stay in that status indefinitely — after the statutory limit, the sponsor either secures full approval or the product comes off the market. That framework is fixed in regulation and is the reason a lifespan indication can realistically reach pharmacy shelves before a decades-long survival study finishes.

The public milestones: Loyal announced in late 2023 that CVM had granted a reasonable expectation of effectiveness for LOY-001 in large-breed dogs, and in early 2025 that LOY-002 had reached the same milestone for its senior-dog indication. Neither is an approval. Each means the agency agreed the effectiveness case is plausible enough to support the conditional pathway.

Loyal has discussed bringing LOY-002 to market once the remaining sections clear. Drug development timelines move, frequently, so treat any projected launch year as a projection and not a plan. If your dog is aging now, talk to your veterinarian about what is available and appropriate today rather than waiting on a pipeline.

How it differs from rapamycin and the Dog Aging Project

Searches for the Loyal dog aging project tend to blend two separate efforts. Loyal is a private company developing proprietary drugs. The Dog Aging Project is an academic research program based at the University of Washington and Texas A&M University, co-founded by Daniel Promislow and Matt Kaeberlein. It runs a large open cohort study of companion dogs and, within it, TRIAD — a randomized, placebo-controlled trial of rapamycin in older companion dogs. The project has sought philanthropic support alongside federal grant funding, and its scale has fluctuated with that funding.

Rapamycin is an mTOR inhibitor already approved in human medicine. It has no FDA approval for canine aging, and dogs receive it only inside a clinical trial or under direct veterinary supervision off-label. It is not something to source independently.

	Loyal LOY-002	Loyal LOY-001 / LOY-003	Rapamycin (TRIAD)
What it is	Daily oral pill	Injectable and oral programs	Existing human drug studied in dogs
Who runs it	Loyal (private company)	Loyal (private company)	Dog Aging Project (academic)
Dogs studied	Senior dogs meeting age and weight criteria	Large and giant breeds	Middle-aged, larger companion dogs
Mechanism focus	Age-related metabolic decline	Lowering IGF-1 signaling	mTOR pathway inhibition
Regulatory route	FDA conditional approval pathway	Same pathway, separate indication	Investigational; no canine aging approval
Available now?	No	No	Only through trial participation or veterinary supervision

Lifespan is the long game — mobility is the next two years

Here is the part that gets lost in longevity coverage. What owners experience as a dog getting old is usually musculoskeletal first: the hesitation at the bottom of the stairs, the refusal to jump onto the couch, the hind end that slides out on the kitchen floor, the shorter walks. Cognitive and organ changes matter, but pain and lost mobility are what drive the hardest conversations.

Whatever happens with LOY-002, the quality of the years your dog has is decided day to day by weight, pain control and mobility — and those are things you and your veterinarian can work on right now.

That work starts with a diagnosis, not a supplement. Osteoarthritis, a partial cruciate ligament tear, intervertebral disc disease, hip dysplasia and endocrine disease all look like slowing down from across the room, and they are managed very differently. Radiographs, an orthopedic exam and bloodwork are what separate them. If your veterinarian prescribes an NSAID, a monoclonal antibody therapy, gabapentin or surgery, that plan is the foundation — nothing in this article is a reason to delay it, substitute for it or stop a prescribed medication. Controlled exercise, lean body condition, traction on slick floors and a structured rehab program do more for an aging dog's function than any bottle on a shelf.

What owners are adding around the veterinary plan

Inside the space a good veterinary plan creates, many owners also want a supportive layer aimed at soft tissue and recovery. That is where peptides have become the category owners are adopting, and it is what pawgen formulates K9-REPAIR around: BPC-157 and TB-500.

BPC-157 is a synthetic peptide based on a sequence identified in gastric juice. Preclinical animal research has examined its role in signaling around tendon, ligament and soft-tissue repair, including effects on fibroblast behavior and the formation of new blood vessels. TB-500 is a synthetic form of an active region of thymosin beta-4, a naturally occurring protein; research has looked at its interaction with actin, cell migration and angiogenesis — the processes tissue uses to reorganize itself after damage. Neither is an FDA-approved veterinary drug, and nothing here is a claim about what will happen in your dog. Research suggests mechanisms that make sense for tissue under repair, early evidence is encouraging, and owners report reaching for this combination through recovery and through the slow-mobility years.

What is worth being skeptical about is the rest of the shelf. Kitchen-sink senior chews stack a dozen ingredients behind a proprietary blend, so you cannot tell how much of anything is in the scoop, and the label does the heavy lifting the formula does not. The questions that separate a serious product from a marketing exercise are simple: what exactly is in it, in what amount, who tested it independently, and can you read that certificate of analysis yourself. pawgen publishes third-party certificates of analysis, doses K9-REPAIR by body weight, ships direct to the door and backs orders with a 60-day money-back guarantee. Bring the ingredient list to your veterinarian and decide together where it fits alongside the prescribed plan — especially for a dog on multiple medications, a puppy, or a pregnant or nursing dog, where dosing questions belong with your vet and nowhere else.

Key takeaways

• LOY-002 is Loyal's daily pill intended to extend healthy lifespan in senior dogs; it is not available for purchase as of early 2026.
• The program is moving through FDA's conditional approval pathway, and Loyal announced a reasonable expectation of effectiveness milestone in early 2025, following a similar milestone for LOY-001 in late 2023.
• Conditional approval permits marketing while effectiveness evidence is still being collected, with annual renewals and a statutory limit — it is not full approval.
• Loyal is a company; the Dog Aging Project is a separate academic program running the TRIAD rapamycin trial. Rapamycin is not approved for canine aging.
• Nothing in the longevity pipeline substitutes for a diagnosis, weight management, pain control and rehab.
• Owners supporting soft tissue and mobility alongside veterinary care have adopted peptide formulations such as K9-REPAIR, which combines BPC-157 and TB-500 and is not an FDA-approved veterinary drug.

Your veterinarian owns the diagnosis and the treatment plan — the imaging, the prescriptions, the surgical decision, the rehab referral. That is not a formality; it is the part that determines how your dog moves next year. Supplements and peptides operate in the space proper veterinary care creates, not in place of it.

More from pawgen: where K9-REPAIR ships, the third-party certificates of analysis, and the full product range.

Owners exploring peptide support for their dog can review K9-REPAIR — BPC-157 + TB-500 formulated for dogs — at https://pawgen.com/. BPC-157 and TB-500 are not FDA-approved veterinary drugs. Nothing in this article treats, cures or prevents any condition; every decision about your dog's care belongs with your veterinarian.